World Journal of Urology

, Volume 37, Issue 1, pp 211–212 | Cite as

A new prognostic model for localized renal cell carcinoma

  • Sebastiano ButiEmail author
Letter to the Editor


Author contributions

SB: idea, manuscript writing/editing

Compliance with ethical standards

Conflict of interest

S. Buti received honoraria for advisory role and as speaker at scientific events from Pfizer, BMS, IPSEN, Pierre-Fabre, Merck Sharp & Dohme (MSD), AstraZeneca; he also received research funding from Novartis.


  1. 1.
    Klatte T, Rossi SH, Stewart GD (2018) Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol. Google Scholar
  2. 2.
    Buti S, Puligandla M, Bersanelli M, DiPaola RS, Manola J, Taguchi S, Haas NB (2017) Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. Ann Oncol 28:2747–2753. CrossRefGoogle Scholar
  3. 3.
    Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS (2005) Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174:466–472CrossRefGoogle Scholar
  4. 4.
    Passalacqua R, Caminiti C, Buti S, Porta C, Camisa R, Braglia L, Tomasello G, Vaglio A, Labianca R, Rondini E, Sabbatini R, Nastasi G, Artioli F, Prati A, Potenzoni M, Pezzuolo D, Oliva E, Alberici F, Buzio C, POLAR-01 Trial Investigators (2014) Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the italian oncology group for clinical research (GOIRC). J Immunother 37:440–447. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Medical Oncology UnitUniversity Hospital of ParmaParmaItaly

Personalised recommendations